Drug reduces invasive disease toll in high-risk early breast cancer: study
Interim results from the open-label trial suggest abemaciclib has benefit, researchers say
AusDoc brings you the latest news from the European Society for Medical Oncology virtual congress 2020.
Combining abemaciclib with endocrine therapy gives better odds of invasive disease-free survival in people with high-risk early breast cancer, researchers report.
In the phase 3 MonarchE trial, more than 5600 people with hormone receptor (HR)-positive and human epidermal growth factor receptor 2 (HER2)-negative disease judged to be at high risk of recurrence were randomised to abemaciclib